CRISPR Therapeutics AG Common Shares
IPOHome | CRISPR Therapeutics
Public · Zug, Switzerland · Founded 2013 · $194.0M raised
- Headquarters
- Zug
- Employees
- 201–500
- Founded
- 2013
- Business Model
- B2B
- Website
- crisprtx.com
- Total Funding
- $194.0M
- Last Round
- $105.0M Corporate RoundSep 2016
- Rounds
- 4
- Type
- Public
About
CRISPR Therapeutics is a clinical-stage gene editing company in Zug, Switzerland, founded 2013 by Emmanuelle Charpentier. CTX001 (exa-cel) approved for sickle cell and beta thalassemia.
Summary
CRISPR Therapeutics AG Common Shares is a Biotech company based in Zug, Switzerland, founded in 2013. It has raised $194.0M in total across 4 rounds, most recently a $105.0M Corporate Round round in Sep 2016. Investors include Bayer AG, Jerel Davis and New Enterprise Associates.
Tech & App Stack
5 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Oct 2016
Sign up to see all 5 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...